FDA clears kidney transplant rejection drug from Astellas

07/22/2013 | PharmaTimes (U.K.) · MedPage Today (free registration)

Astellas Pharma obtained the FDA's approval to market Astragraf XL, an extended-release version of the firm's Prograf, or tacrolimus, for prevention of kidney transplant rejection. The approval makes Astragraf XL the first once-daily tacrolimus formulation available to kidney transplant patients in the U.S. The approval was based on data from two late-stage trials involving 1,093 patients.

View Full Article in:

PharmaTimes (U.K.) · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN